First Manhattan
AXSM icon

First Manhattan’s Axsome Therapeutics AXSM Stock Holding History

First Manhattan’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-300
Closed -$23.9K – 715
2024
Q1 		$23.9K Hold
300
– – ﹤0.01% 1005
2023
Q4 		$23.9K Hold
300
– – ﹤0.01% 994
2023
Q3 		$21K Buy
300
+200
+200% +$15K ﹤0.01% 1016
2023
Q2 		$7.19K Hold
100
– – ﹤0.01% 1185
2023
Q1 		$6.17K Buy
+100
New +$6.57K ﹤0.01% 1265
2019
Q1 		– Sell
-1,100
Closed -$3K – 1385
2018
Q4 		$3K Buy
+1,100
New +$3.62K ﹤0.01% 1266

Other funds holding AXSM

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

First Manhattan's AXSM Position: Q2 2024 in Review

First Manhattan sold out of Axsome Therapeutics (AXSM) in Q2 2024, closing a stake of 300 shares — an estimated $23.9K sold.

First Manhattan first reported a position in AXSM in Q4 2018 and held it in 6 quarters. The position peaked at $23.9K in Q1 2024. 256 funds tracked by Wall St. Rank hold AXSM as of Q2 2024.

  • First Manhattan reported no remaining Axsome Therapeutics position as of Q2 2024 after selling out during the quarter.
  • First Manhattan sold 300 Axsome Therapeutics shares in Q2 2024, an estimated $23.9K.
  • First Manhattan first reported a position in Axsome Therapeutics in Q4 2018 and held it in 6 quarters.
  • First Manhattan's Axsome Therapeutics position peaked at $23.9K in Q1 2024.
  • 256 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2024.

Based on First Manhattan's 13F filing for Q2 2024, filed 14 Aug 2024.